Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegloticase SC vs IV with MTX in Uncontrolled Gout
NCT07388498Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Feb 2026
- Primary completion
- Jun 2028
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of pegloticase in gout, sponsored by Amgen. Started Feb 2026; status: recruiting.
02
Drugs
pegloticase
03
Conditions
gout
Beyond the preview
Go deeper on NCT07388498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388498.